Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment

Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been established. The present investigation is directed t...

Full description

Bibliographic Details
Main Authors: Eva Juengel, Pascal Schnalke, Jochen Rutz, Sebastian Maxeiner, Felix K.-H. Chun, Roman A. Blaheta
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Biomedicines
Subjects:
renal cell carcinoma
tyrosine kinase inhibitors
endothelial cells
resistance
second-line
Online Access:https://www.mdpi.com/2227-9059/9/11/1630

Internet

https://www.mdpi.com/2227-9059/9/11/1630

Similar Items